The use of phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide
A full-term, male neonate developed persistent pulmonary hypertension, and responded to high-frequency oscillatory ventilation and inhaled nitric oxide (INO). Discontinuation of INO was attempted three times and was followed by severe desaturations due to right-to-left shunt through the patent ductus arteriosus and patent foramen ovale. As a result of this rebound pulmonary hypertension, the neonate was maintained on INO therapy for 6 days. Successful discontinuation was achieved by using the phosphodiesterase inhibitor, dipyridamole. We speculate that during exogenous INO therapy, endogenous nitric oxide was inhibited, thus cyclic guanosine 3′,5′-monophophate, the smooth muscle relaxant, was rapidly hydrolyzed. By inhibiting phosphodiesterase, smooth muscle relaxation occurred, and consequently weaning from INO was achieved.
Key wordsNeonates Phosphodi-esterase inhibitor Nitric oxide Pulmonary hypertension
Unable to display preview. Download preview PDF.
- 1.Kinsella JP, Neish SR, Dunbar I, Shaffer E, Abman SH (1993) Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr 123: 103–108Google Scholar
- 2.Roberts JD, Polaner DM, Lang P, Zapol WM (1992) Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340:818–819Google Scholar
- 3.Kinsella JP, Neish SR, Shaffer E, Abman SH (1992) Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 340: 819–820Google Scholar
- 4.Griffith TM, Edwards DH, Lewis MJ, Henderson AH (1985) Evidence that cyclic guanosine monophosphate (cGMP) mediates endothelium-dependent relaxation. Eur J Pharmacol 112: 195–202Google Scholar
- 5.Bult H, De Meyer GRY, Jordaens FH, Herman AG (1991) Chronic exposure to exogenous nitric oxide may suppress its endogenous release and efficacy. J Cardiovasc Pharmacol 17 [Suppl 3]: S79-S82Google Scholar
- 6.Alfonso S, O'Brien GS (1971) Mechanism of enhancement of adenosine action by dipyridamole and lidoflazine in dogs. Arch Int Pharmacodyn Ther 194: 181–196Google Scholar
- 7.Klabunder RE (1983) Effects of dipyridamole on post-ischemic vasodilatation and extracellular adenosine. Am J Physiol 244: H273-H280Google Scholar
- 8.Scharder JR, Berne M, Rubio R (1973) Uptake and metabolism of adenosine by human erythrocyte ghosts. Am J Physiol 223:159–166Google Scholar
- 9.Beavo JA, Reifsynder DH (1990) Primary sequence of cyclic nucleotide phosphodiesterase isoenzymes and the design of selective inhibitors. Trends Pharmacol Sci 11: 150–155Google Scholar
- 10.Ziegler JW, Ivy DD, Fox JJ, Kinsella JP, Clarke WR, Abman SH (1995) Dipyridamole, a cGMP phosphodiesterase inhibitor, causes pulmonary vasodilatation in the ovine fetus. Am J Physiol 269:H473-H479Google Scholar
- 11.Kinsella JP, Torielli F, Ziegler JW, Ivy DD, Abman S (1995) Dipyridamole augmentation of response to nitric oxide. Lancet 346: 647–648Google Scholar